Lubiprostone: Difference between revisions
(Creation of Page) |
ClaireLewis (talk | contribs) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Laxative | *Type: [[Laxative]] | ||
*Dosage Forms: CAP 8mcg, 24mcg | *Dosage Forms: CAP 8mcg, 24mcg | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
| Line 14: | Line 14: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Safety/efficacy not established in pediatric patients | |||
==Special Populations== | ==Special Populations== | ||
| Line 67: | Line 67: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:GI]] | ||
Latest revision as of 22:59, 22 September 2019
Administration
- Type: Laxative
- Dosage Forms: CAP 8mcg, 24mcg
- Routes of Administration: Oral
- Common Trade Names: Amitiza
Adult Dosing
Chronic idiopathic constipation
- 24mcg PO BID
IBS, constipation predominant
- 8mcg PO BID
Constipation, opioid-induced
- 24mcg PO BID
Pediatric Dosing
Safety/efficacy not established in pediatric patients
Special Populations
- Pregnancy Rating: C
- Lactation risk: Risk of infant harm not expected based on minimal absorption.
Renal Dosing
- Adult: No adjustment
- Pediatric: Not available
Hepatic Dosing
- Adult:
- Child-Pugh Class C: 8mcg qd
- Pediatric: Not available
Contraindications
- Allergy to class/drug
- GI Obstruction
- Diarrhea, severe
Adverse Reactions
Serious
- Diarrhea, severe
- Hypersensitivity reaction
- Syncope
- Hypotension
Common
- Nausea, headache, vomiting, dizziness
- Diarrhea
- Abdominal pain
- Flatulence
- Sinusitis
- UTI, URI
- Peripheral edema
- Arthralgia, fatigue, dyspnea
Pharmacology
- Half-life: 0.9-1.4h
- Metabolism: Stomach
- Excretion: Urine (60%), Feces (30%)
Mechanism of Action
- Activates CIC-2 chloride channels, increasing intestinal fluid secretion and motility
- Reduces intestinal permeability and stimulates recovery of mucosal barrier function